Loading...

Japan’s generics market woos Indian firms

Image

16-Nov-15 Japan, with sales of USD115, accounts for 10% of the global pharma market, compared with 38% for the US and 21% for Europe. Lupin is the only Indian company in Japan's generics market. But now Sun Pharmaceuticals is planning to acquire Novartis' Japanese drug portfolio. Other Indian generics makers, including Dr Reddy’s and Glenmark, are also exploring options. [image: Bloomberg]

Read More

Zimmer Biomet achieving synergies and rapid sales in Asia-Pacific

Image

03-Nov-15 In the first quarter after its merger, Zimmer Biomet has reported it expects to complete commercial integration by the end of 2015. It also reported progress on its sales channel integration, evidenced by sequential sales improvement in its Asia-Pacific and Europe, Middle East & Africa (EMEA) regions, where Knee orthopaedics sales increased 9% and 6% respectively. [image: Zimmer Biomet]

Read More

China's Sinocare to buy Nipro Diagnostics

Image

03-Nov-15 Chinese diabetes tech firm Sinocare has signed an agreement to acquire Nipro Diagnostics from Japan's Nipro Corp, for USD273 mn. Nipro Diagnostics is based in Florida and manufacturers products for people with diabetes, including a portfolio of blood glucose monitoring technologies. Sinocare CEO Shaobo Li said “Diabetes has become one of the biggest challenges to our public healthcare system and society." [image: Sinocare]

Read More
Share